Athersys

Athersys Net Debt/Equity

Delisted·Oct 1, 2026

The Net Debt to Equity Ratio of Athersys (ATHXQ) as of Nov 20, 2026 is -1.18. In the previous year, Net Debt to Equity Ratio was -1.25 — a change of -5.58% (higher).

Net Debt/Equity

-1.18

YoY

-5.58%

Last updated:

Net Debt to Equity Ratio of Athersys is 2018 -1.18 . Net Debt to Equity Ratio of Athersys was 2017 -1.25 . It decreases by -5.58% higher compared to the previous year.

The Athersys Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2014
-1.24 USD
Jan 1, 2015
-1.16 USD
Jan 1, 2016
-1.32 USD
Jan 1, 2017
-1.25 USD
Jan 1, 2018
-1.18 USD
The Athersys Net Debt/Equity history
YEARNet Debt/EquityYoY
-1.18-5.58%
-1.25-4.95%
-1.32+13.91%
-1.16-6.72%
-1.24—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Athersys Stock analysis

What does Athersys do? Athersys, Inc. generates revenue through the development and commercialization of its MultiStem (invimestrocel) cell therapy, an allogeneic stem cell product candidate derived from adult bone marrow. The company focuses on late-stage clinical development for critical care, neurological conditions, inflammatory disorders, pulmonary conditions, and cardiovascular disease. Its lead product, MultiStem, is currently in Phase III clinical trials for ischemic stroke under the MASTERS-2 study. Athersys targets medical institutions and healthcare providers seeking innovative treatments for unmet medical needs in multiple disease areas. The company's primary product, MultiStem, is manufactured from human stem cells obtained from adult bone marrow and alternative tissue sources. It is designed to address conditions including critical care indications, neurological disorders, inflammatory and immune disorders, pulmonary conditions, and cardiovascular disease. Athersys conducts Phase III trials for ischemic stroke treatment, aiming to secure regulatory approval for broader market access. Revenue streams are expected to emerge post-approval through therapeutic product sales to hospitals and clinics. Athersys, Inc. operates in the biotechnology sector with a focus on regenerative medicine, leveraging its MultiStem platform to address unmet medical needs. The company's clinical development strategy centers on late-stage trials for ischemic stroke and other conditions, targeting healthcare providers and medical institutions as key customers. Commercialization of MultiStem will likely involve partnerships with healthcare systems for treatment protocols and patient access. Athersys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athersys stock

Net Debt to Equity Ratio of Athersys is -1.18 in 2018.

Net Debt to Equity Ratio of Athersys changed from -1.25 to -1.18, representing a -5.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Athersys since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Athersys with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Athersys

All Key Metrics — Athersys